Evotec AG O.N. stock collapsed during trading after the company issued an unexpected profit warning late on Monday, with the share price sliding about 32.5% to an intraday low of €3.176 and trading around €3.336 at the time of reporting. The move followed preliminary first-half results and a sweeping downward revision to the full-year outlook.
The preliminary financials revealed group revenue for H1 2026 of €300.1 million, down from €371.1 million in the same period a year earlier. Adjusted EBITDA swung into a larger loss, widening to a €42.7 million deficit compared with a €1.9 million loss in H1 2025.
More damaging to market confidence was the guidance change: Evotec trimmed its full-year 2026 revenue forecast to a range of €570 to €610 million, down from a prior guidance range of €700 to €780 million. The company also reversed its adjusted EBITDA expectation, moving from a projected profit of up to €40 million to a projected loss between €70 million and €105 million.
Management identified two primary contributors to the revenue shortfall. Roughly 40% of the miss was attributed to delayed milestone payments from existing partnerships, while about 45% was blamed on slower-than-expected progress in closing new strategic collaborations. Those explanations were set out in the company communication accompanying the preliminary figures.
An analyst covering the stock labeled the update as "another significant profit warning" and urged the company to accelerate financial transparency and provide more detailed forecasts to help restore investor trust.
The sell-off was driven by company-specific news rather than a broader German market slump. The DAX was trading modestly higher on the day, indicating the decline in Evotec shares was idiosyncratic. U.S. markets were softer overall, with the S&P 500 down 0.8% and the Nasdaq off 1.6%, creating a mildly risk-off global backdrop, but those moves did not account for the scale of Evotec's drop.
The stock had already been under pressure in recent months, and the fresh downgrade accelerated that trend, pushing the share price toward its lowest level in roughly a decade. The intraday low of €3.176 established a new 52-week trough, well below the prior 52-week low, as selling pressure overwhelmed buyers seeking an entry point.
Investors reacted sharply to the combination of a much larger-than-expected negative EBITDA revision, a revenue guidance cut approaching 20%, and an ongoing pattern of forecast misses. While management highlighted progress under the Horizon transformation program and pointed to a pipeline that includes oncology and nephrology opportunities, the market response was swift and severe.
Key points
- Evotec reported H1 2026 revenue of €300.1 million and an adjusted EBITDA loss of €42.7 million, both worse than the prior year.
- Full-year 2026 revenue guidance was lowered to €570-610 million from €700-780 million; adjusted EBITDA swung to a forecast loss of €70-105 million from an expected profit of up to €40 million.
- Sectors affected include biotech and health-care services, with potential spillover to investor sentiment in small-cap biotech and contract research segments.
Risks and uncertainties
- Timing risk around milestone payments - roughly 40% of the revenue shortfall is linked to delayed payments from existing partners, creating near-term revenue uncertainty for the company and affecting cash flow expectations in the biotech services sector.
- Deal-closure risk - about 45% of the miss stems from slower progress in securing new strategic collaborations, heightening uncertainty around future revenue growth and strategic execution in partnerships.
- Market confidence risk - repeated forecast misses and a large negative EBITDA revision have eroded investor trust, increasing stock volatility and pressure on the company’s access to equity markets if further capital is needed.